SCHEMBL15420519

SCHEMBL15420519

CS(=O)(=O)N[C@H]1CCCO[C@@H]1COc1ccc(-c2ccc(C#N)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 4/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TNF P01375 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
HCRTR2 O43614 1/20 0.35
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
CCR6 P51684 2/20 0.34
CTSC P53634 1/20 0.34
KDM1A O60341 1/20 0.34
GRIA4 P48058 1/20 0.34
GPR183 P32249 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
NPC1 O15118 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15420096 0.92 KDM4E (0.45) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL15420860 0.90 KDM4E (0.41) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL15420610 0.88 GRIA2 (0.38) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL15420211 0.88 GRIA2 (0.42) KDM4EALDH1A1HPGDTNFLMNA
SCHEMBL15420325 0.81 KDM4E (0.46) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL15420497 0.81 KDM4E (0.43) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL15420594 0.80 CXCR1 (0.37) KDM4EALDH1A1HPGDTNFLMNA
SCHEMBL15420746 0.80 TP53 (0.44) LMNAMAPK1MAPTNPC1
SCHEMBL15420525 0.80 LMNA (0.51) KDM4EALDH1A1HPGDHTTLMNA
SCHEMBL15420142 0.80 NPC1 (0.41) ALDH1A1HPGDHTTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 KDM4E 2112/4885ALDH1A1 143/4885HPGD 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.